John Milligan, president and chief operating officer of Gilead Sciences Inc., speaks during an interview in New York, U.S., on Tuesday, Feb. 11, 2014. Gilead Sciences Inc., the world's largest maker of HIV medicines, received U.S. approval in December for Sovaldi, the treatment for hepatitis C it acquired in its $11 billion purchase of Pharmasset Inc. in 2012. Photographer: Victor J. Blue/Bloomberg via Getty Images
Getty Images

Bloomberg Bloomberg